Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years
Open Access
- 10 November 2014
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 50 (2), 209-215
- https://doi.org/10.1038/bmt.2014.255
Abstract
Autologous hematopoietic cell transplantation (AHCT) is a standard of care in multiple myeloma (MM) patients aged P<0.001) were calendar period, remission status at AHCT, gender, disease duration before AHCT and age. Survival improved considerably more in older than in younger patients in recent years. In 2006–2010, median 2- and 5-year post-transplant survival ranged from 85.9 and 61.5% in patients <40 years to 80.2 and 49.7% in those ⩾70 years. All-cause day-100 mortality decreased throughout the observation period to ⩽2.4% for all age groups in 2006–2010. The results of this study demonstrate increased utilisation and safety of AHCT with improved post-transplant survival particularly in elderly MM patients in recent years in Europe.Keywords
This publication has 44 references indexed in Scilit:
- Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated resultsBlood, 2013
- Improvement in Survival of Older Adults with Multiple Myeloma: Results of an Updated Period Analysis of SEER DataThe Oncologist, 2011
- Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myelomaLeukemia & Lymphoma, 2011
- Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based StudyJournal of Clinical Oncology, 2010
- Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989European Journal Of Cancer, 2010
- International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantationLeukemia, 2009
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Recent major improvement in long-term survival of younger patients with multiple myelomaBlood, 2008
- Epidemiology and outcomes research for MGUS, myeloma and amyloidosisEuropean Journal Of Cancer, 2006
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998